Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1996 1
1998 18
1999 7
2000 11
2001 16
2002 30
2003 40
2004 43
2005 37
2006 58
2007 36
2008 42
2009 38
2010 34
2011 36
2012 24
2013 23
2014 24
2015 29
2016 22
2017 15
2018 11
2019 16
2020 12
2021 18
2022 8
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

617 results

Results by year

Filters applied: . Clear all
Page 1
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P. Howard R, et al. N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668. N Engl J Med. 2012. PMID: 22397651 Free article. Clinical Trial.
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 3 …
METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate o …
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, Cansfield JE, Cross DM, de Graaf C, Hudson BD, Dwomoh L, Dias JM, Errey JC, Hurrell E, Liptrot J, Mattedi G, Molloy C, Nathan PJ, Okrasa K, Osborne G, Patel JC, Pickworth M, Robertson N, Shahabi S, Bundgaard C, Phillips K, Broad LM, Goonawardena AV, Morairty SR, Browning M, Perini F, Dawson GR, Deakin JFW, Smith RT, Sexton PM, Warneck J, Vinson M, Tasker T, Tehan BG, Teobald B, Christopoulos A, Langmead CJ, Jazayeri A, Cooke RM, Rucktooa P, Congreve MS, Weir M, Tobin AB. Brown AJH, et al. Cell. 2021 Nov 24;184(24):5886-5901.e22. doi: 10.1016/j.cell.2021.11.001. Cell. 2021. PMID: 34822784 Free PMC article. Clinical Trial.
Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.
Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Bago Rožanković P, et al. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. Cogn Behav Neurol. 2021. PMID: 34851866 Clinical Trial.
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) are common in individuals with Alzheimer disease (AD). Donepezil and memantine are both widely used for the treatment of moderate AD. OBJECTIVE: To evaluate the effects of donepezil and memantine i …
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) are common in individuals with Alzheimer disease (AD). Donepezil …
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. Rogers SL, et al. Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136. Neurology. 1998. PMID: 9443470 Clinical Trial.
Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157) for 24 weeks followed by a 6-week, single-blind placebo washout. ...Cognitive function, as measured by the ADAS-cog, was significantly imp …
Patients were randomly assigned to treatment with placebo (n = 162), 5 mg/d donepezil (n = 154), or 10 mg/d donepezil (n = 157 …
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Tariot PN, et al. JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled clinical trial of 404 patients …
OBJECTIVE: To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatm …
Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial.
Osataphan N, Phrommintikul A, Leemasawat K, Somwangprasert A, Apaijai N, Suksai S, Sirikul W, Gunaparn S, Chattipakorn SC, Chattipakorn N. Osataphan N, et al. Sci Rep. 2023 Aug 7;13(1):12759. doi: 10.1038/s41598-023-40061-4. Sci Rep. 2023. PMID: 37550350 Free PMC article. Clinical Trial.
Metformin and donepezil did not attenuate hsTnI elevation, LVEF or GLS reduction. There was no significant change in NT-proBNP level. Mitochondrial respiratory dysfunction was observed in the placebo and donepezil groups. However, metformin preserved mitochondrial r …
Metformin and donepezil did not attenuate hsTnI elevation, LVEF or GLS reduction. There was no significant change in NT-proBNP level. …
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients with Mild to Moderate Alzheimer's Disease Treated with Donepezil: DHP1401 Randomized Trial in Mild to Moderate Alzheimer's Disease (DRAMA).
Shim Y, Han HJ, Park KW, Kim BC, Park KH, Park MY, Kim HJ, Moon SY, Choi SH, Park KW, Yang DW, Yoon SJ, Kim SY, Youn YC, Choi H, Yoon KE, Cho HJ, Han SH. Shim Y, et al. J Alzheimers Dis. 2022;87(1):391-403. doi: 10.3233/JAD-215277. J Alzheimers Dis. 2022. PMID: 35275529 Clinical Trial.
However, in the subgroup with mild AD patients (MMSE, 20-26) who received the high dose of DHP1401 and the group that received donepezil 5 mg, the ADAS-cog scores improved. MMSE and K-TMT-e type B were significant in both active groups at week 24. ...
However, in the subgroup with mild AD patients (MMSE, 20-26) who received the high dose of DHP1401 and the group that received donepezil …
Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial.
Koh SH, Kwon HS, Choi SH, Jeong JH, Na HR, Lee CN, Yang Y, Lee AY, Lee JH, Park KW, Han HJ, Kim BC, Park JS, Lee JY, Kim S, Lee KY. Koh SH, et al. Alzheimers Res Ther. 2021 Mar 26;13(1):66. doi: 10.1186/s13195-021-00803-w. Alzheimers Res Ther. 2021. PMID: 33771205 Free PMC article. Clinical Trial.
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial.
Lee W, Kim M. Lee W, et al. Medicine (Baltimore). 2024 Jun 14;103(24):e38067. doi: 10.1097/MD.0000000000038067. Medicine (Baltimore). 2024. PMID: 38875437 Free PMC article. Clinical Trial.
The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cognitive decline in Alzheimer disease. This study aims to replicate the effect by combining donepezil with other nootropics currently used in South Korea. METHODS: The 119 patients with …
The ASCOMALVA trial, a combination of donepezil and choline alfoscerate, slowed cognitive decline in Alzheimer disease. This study ai …
Durable recovery from amblyopia with donepezil.
Wu C, Gaier ED, Nihalani BR, Whitecross S, Hensch TK, Hunter DG. Wu C, et al. Sci Rep. 2023 Jun 22;13(1):10161. doi: 10.1038/s41598-023-34891-5. Sci Rep. 2023. PMID: 37349338 Free PMC article. Clinical Trial.
Motivated by these promising findings, we sought to determine whether donepezil, a commercially available AChEI, can enable recovery in older children and adults with residual amblyopia. ...Gains were maintained 10 weeks after cessation of donepezil and were similar …
Motivated by these promising findings, we sought to determine whether donepezil, a commercially available AChEI, can enable recovery …
617 results